Stay updated on Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedRevision label updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no visible changes to the study details, eligibility criteria, or contacts were identified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedThe update shows a minor version bump from v3.4.0 to v3.4.1 with no user-facing changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedAdded a Show glossary toggle and new metadata fields (Last Update Submitted that Met QC Criteria) plus a No FEAR Act Data note and a Revision: v3.4.0. These are UI and metadata updates that do not change the core study content or enrollment details.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision label on the page updated from v3.3.3 to v3.3.4; no substantive study content was altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a consolidated Locations section listing nine study sites across Kansas, Missouri, and Texas, replacing the previous state-specific sections (Kansas Locations, Missouri Locations, Texas Locations). The page revision updated to v3.3.3.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial page.